Myeloid cells in sepsis-acquired immunodeficiency

Venet, Fabienne; Demaret, Julie; Gossez, Morgane; Monneret, Guillaume

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1111/nyas.14333

PMID :

32202669

URL permanente :

http://hdl.handle.net/20.500.12210/40710

Titre :

Myeloid cells in sepsis-acquired immunodeficiency

Auteur(s) :

Venet, Fabienne [Auteur]
Demaret, Julie [Auteur]

Gossez, Morgane [Auteur]
Monneret, Guillaume [Auteur]

Titre de la revue :

Annals of the New York Academy of Sciences

Nom court de la revue :

Ann. N. Y. Acad. Sci.

Date de publication :

2020-03-23

ISSN :

1749-6632

Mot(s)-clé(s) :

HLA-DR
immunodeficiency
immunosuppression
MDSC
sepsis
myeloid
monocyte

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

On May 2017, the World Health Organization recognized sepsis as a global health priority. Sepsis profoundly perturbs immune homeostasis by initiating a complex response that varies over time, with the concomitant occurrence ...
Lire la suite >On May 2017, the World Health Organization recognized sepsis as a global health priority. Sepsis profoundly perturbs immune homeostasis by initiating a complex response that varies over time, with the concomitant occurrence of pro- and anti-inflammatory mechanisms. Sepsis deeply impacts myeloid cell response. Different mechanisms are at play, such as apoptosis, endotoxin tolerance, metabolic failure, epigenetic reprogramming, and central regulation. This induces systemic effects on circulating immune cells and impacts progenitors locally in lymphoid organs. In the bone marrow, a progressive shift toward the release of immature myeloid cells (including myeloid-derived suppressor cells), at the expense of mature neutrophils, takes place. Circulating dendritic cell number remains dramatically low and monocytes/macrophages display an anti-inflammatory phenotype and reduced antigen presentation capacity. Intensity and persistence of these alterations are associated with increased risk of deleterious outcomes in patients. Thus, myeloid cells dysfunctions play a prominent role in the occurrence of sepsis-acquired immunodeficiency. For the most immunosuppressed patients, this paves the way for clinical trials evaluating immunoadjuvant molecules (granulocyte-macrophage colony-stimulating factor and interferon gamma) aimed at restoring homeostatic myeloid cell response. Our review offers a summary of sepsis-induced myeloid cell dysfunctions and current therapeutic strategies proposed to target these defects in patients.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:47:40Z

Numéro de version	Lien	Date de modification
2	20.500.12210/40710	2024-01-24T10:54:07Z
1	20.500.12210/40710.1*	2021-07-06T12:47:40Z

Myeloid cells in sepsis-acquired immunodeficiency

BibTeX

CSV

Excel

RIS

Information

Historique des modifications

Myeloid cells in sepsis-acquired immunodeficiency BibTeX CSV Excel RIS

Information

Historique des modifications

Myeloid cells in sepsis-acquired immunodeficiency

BibTeX

CSV

Excel

RIS